Drug Trial Radar · NCT04829123
The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Feb 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
May 14, 2021
Primary completion
Mar 2, 2022
Study completion Mar 2, 2022
Sponsor
- Lead sponsor
- Dongguan HEC Biopharmaceutical R&D Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 1, double blind, placebo controlled, single and multiple ascending dose, safety, tolerability, pharmacokinetic, and pharmacodynamic study of HEC88473 in healthy subjects
Conditions
- Non-alcoholic Steatohepatitis
Interventions
HEC88473 injectionDrug
HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen
PlaceboDrug
Placebo will be administered by subcutaneous injection in the abdomen
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) after a single dose of HEC88473Time frame: Baseline to day 15
- Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) after multiple dose of HEC88473Time frame: Baseline to day 43
- CmaxTime frame: Predose and postdose 4, 8, 10, 12, 14, 24, 48, 72, 96, 168, 216, and 336 hours
- AUCTime frame: Predose and postdose 4, 8, 10, 12, 14, 24, 48, 72, 96, 168, 216, and 336 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Scientia Clinical Research
Sydney, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.